About Zydus Lifesciences Ltd
Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.(Source : 202503-Annual Report Page No:291)
Founded
1995
CEO
Pankaj R Patel
Employees
36,827
HQ
Ahmedabad, India
Finished Products
1Sale of Products
₹51,995.30Cr2Other Operating Revenues
₹896.70Cr3Contract Manufacturings
₹376.00Cr4Export Incentives
₹350.60Cr5Others
₹262.80Cr6Netgain on Foreign CurrencyTr.
₹145.00Cr7Licence Fees
₹80.60Cr1–7 of 9
Raw Materials
1Raw Material Consumed
₹13,686.00Cr2Purchases of Finished Goods
₹1,284.90Cr3Packing Materials
₹965.70Cr4Purchases of Stock in Trade
₹197.70CrAbout Zydus Lifesciences Ltd
Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.(Source : 202503-Annual Report Page No:291)
Founded:1995
CEO:Pankaj R Patel
Employees:36,827
HQ:Ahmedabad, India
Finished Products
1Sale of Products
₹51,995.30Cr2Other Operating Revenues
₹896.70Cr3Contract Manufacturings
₹376.00Cr4Export Incentives
₹350.60Cr5Others
₹262.80Cr6Netgain on Foreign CurrencyTr.
₹145.00Cr7Licence Fees
₹80.60Cr1–7 of 9
Raw Materials
1Raw Material Consumed
₹13,686.00Cr2Purchases of Finished Goods
₹1,284.90Cr3Packing Materials
₹965.70Cr4Purchases of Stock in Trade
₹197.70CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹1,205
52W Low
₹836
Volume1.38M
Avg VolumeN/A
Beta0.69
Dividend Yield0.09%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
25.28x
Valuation
P/B Ratio
4.28x
Valuation
EPS
₹46.04
Valuation
Dividend Yield
0.09%
Valuation
ROE
18.59%
Profitability
ROCE
17.35%
Profitability
Revenue by Segment
Contribution & growth by business line
Pharmaceuticals
+9.1%82.6%
₹22,412.1 Cr
Consumer Products
+46.6%14.6%
₹3,954 Cr
Medical technologies
+32495.8%2.9%
₹782.3 Cr
Geographical Revenue Split
Domestic vs international exposure
Domestic
35.8%
International
64.2%
US43.2%
India35.8%
Others11.2%
Europe9.9%
Strategic Relations
Collaborations, joint ventures & subsidiaries
E
Ethical Holdings Plc
United Kingdom
0.00% stakeB
Beta Pharmaceuticals Corporation
Uruguay
0.00% stakeE
Ethical Pharmaceuticals South America SA
Argentina
0.00% stakeForensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.46x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
37.8%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.